[ad_1]
Qure.ai has two flagship merchandise—qER and qXR—in combating TBI and lung illness. The qXR instrument delivers automated chest x-ray interpretation. The expertise precisely detects irregular chest x-ray findings and can be utilized to differentiate between regular and irregular x-ray findings, for pre-read help, or as a radiology audit instrument.
The qER instrument (for TBI and stroke detection) can detect intracranial hemorrhages, subdural bleeds, midline shift, and mass impact (for tumor detection) to supply fast and correct head CT scan evaluation. It has 32 collective peer assessment journals and convention papers beneath its belt, together with a assessment in The Lancet.
Qure.ai reads and interprets medical pictures like X-rays, CTs, and ultrasounds in lower than a minute. Its AI options are FDA-approved, CE-certified, and evaluated by the World Well being Organisation.
Prashant Warier, CEO and founding father of Qure.ai, stated, “Within the final two years, we now have obtained 3 FDA clearances throughout 12 completely different capabilities and CE certifications throughout all our merchandise and scaled 10-15 instances when it comes to income. We’re current in 50 international locations touching 4 million lives on an annualized foundation. We now have round 100 merchandise and we plan to broaden our footprint organically and inorganically,” he stated.
Amit Kakar, senior associate, head of Novo Holdings Fairness Asia, stated, “Qure.ai is enabling entry to healthcare and prognosis of essential illnesses TB, stroke, lung nodules resulting in lung most cancers and that mixture on the intersection of healthcare and tech is one thing that made Qure.ai extraordinarily engaging to us from an funding perspective,” he stated.
[ad_2]
Source link